Magnetic iron oxide nanoparticles (MIONs) cross‐linked natural polymer‐based hybrid gel beads: Controlled nano anti‐TB drug delivery application. Issue 4 (21st December 2017)

• Record Type: Journal Article
• Authors: Kesavan, Mookkandi Palsamy; Ayyanaar, Srinivasan; Vijayakumar, Vijayaparthasarathi; Dhaveethu Raja, Jeyaraj; Annaraj, Jamespandi; Sakthipandi, Kathiresan; Rajesh, Jegathalaprathaban
• Is Part Of: Journal of biomedical materials research. Volume 106:Issue 4(2018)
• Page Start: 1039
• Page End: 1050
• Publication Date: 2017-12-21
• Subjects: nano RIF -- mCS‐PEG gel beads -- swelling studies -- dual responsive nano drug delivery; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.36306
• Languages: English
• ISSNs: 1549-3296

Abstract

Abstract: The nanosized rifampicin (RIF) has been prepared to increase the solubility in aqueous solution, which leads to remarkable enhancement of its bioavailability and their convenient delivery system studied by newly produced nontoxic, biodegradable magnetic iron oxide nanoparticles (MIONs) cross‐linked polyethylene glycol hybrid chitosan (mCS‐PEG) gel beads. The functionalization of both nano RIF and mCS‐PEG gel beads were studied using various spectroscopic and microscopic techniques. The size of prepared nano RIF was found to be 70.20 ± 3.50 nm. The mechanical stability and swelling ratio of the magnetic gel beads increased by the addition of PEG with a maximum swelling ratio of 38.67 ± 0.29 g/g. Interestingly, this magnetic gel bead has dual responsive assets in the nano drug delivery application (pH and the magnetic field). As we expected, magnetic gel beads show higher nano drug releasing efficacy at acidic medium (pH = 5.0) with maximum efficiency of 71.00 ± 0.87%. This efficacy may also be tuned by altering the external magnetic field and the weight percentage (wt%) of PEG. These results suggest that such a dual responsive magnetic gel beads can be used as a potential system in the nano drug delivery applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1039–1050, 2018.